Representatives of the myotubular and centronuclear myopathy patient organisations recently met with Audentes Therapeutics in our continuing effort to best support the community.

The focus of the meeting was to better understand the drug development process and to discuss how best to communicate information. Part of the discussion included gaining a better understanding of general regulatory and ethical considerations and processes related to clinical trials and the clinical development program for x-linked myotubular myopathy (XLMTM). We are hopeful that the knowledge gained on these topics will allow us to better communicate with the MTM/CNM patient and family communities as we move forward.